ImmunityBio (NASDAQ:IBRX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $17.50 million for the quarter.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ImmunityBio Stock Performance
ImmunityBio stock traded up $0.05 during midday trading on Friday, reaching $2.54. The stock had a trading volume of 3,784,427 shares, compared to its average volume of 5,134,925. ImmunityBio has a 1-year low of $2.28 and a 1-year high of $9.48. The firm's fifty day simple moving average is $2.78 and its 200-day simple moving average is $3.43. The stock has a market capitalization of $2.17 billion, a P/E ratio of -2.76 and a beta of 0.51.
Wall Street Analyst Weigh In
Several brokerages recently commented on IBRX. BTIG Research started coverage on shares of ImmunityBio in a report on Friday, January 10th. They set a "buy" rating and a $6.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of ImmunityBio in a report on Monday, April 28th. Finally, D. Boral Capital reiterated a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $12.19.
Read Our Latest Analysis on ImmunityBio
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Recommended Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
